Stawowski A, Konopinska J, Stawowski S, Adamczuk J, Groth M, Moniuszko-Malinowska A
Clin Ophthalmol. 2024; 18:1417-1432.
PMID: 38803556
PMC: 11129748.
DOI: 10.2147/OPTH.S460224.
Shil R, Dunai C, Seed A, Wood G, Collie C, Pendered S
Clin Med (Lond). 2024; 23(Suppl 6):40.
PMID: 38182203
PMC: 11046651.
DOI: 10.7861/clinmed.23-6-s40.
Massey D, Sawano M, Baker A, Guthe D, Guthe N, Shidlovsky S
BMJ Open. 2023; 13(12):e077389.
PMID: 38154880
PMC: 10759066.
DOI: 10.1136/bmjopen-2023-077389.
Poyraz T, Varol A, Uysal H
Noro Psikiyatr Ars. 2023; 60(4):376-379.
PMID: 38077842
PMC: 10709712.
DOI: 10.29399/npa.28205.
Pillai K, Misra S, Siripurapu G, Aliyar A, Bhat P, Rajan R
Ann Indian Acad Neurol. 2023; 26(5):702-707.
PMID: 38022478
PMC: 10666879.
DOI: 10.4103/aian.aian_572_23.
Opsoclonus-Myoclonus-Ataxia Syndrome Due to Covid-19.
Adamaszek M, Langner S, Mehrholz J, Heiinrich A
Cerebellum. 2023; 23(3):1245-1248.
PMID: 37814146
DOI: 10.1007/s12311-023-01610-9.
Movement Disorders and SARS-CoV-2.
Fung W, Fasano A, Fearon C
Mov Disord Clin Pract. 2023; 10(Suppl 2):S9-S17.
PMID: 37637980
PMC: 10448146.
DOI: 10.1002/mdc3.13615.
Retrospective analysis of COVID-19 patients with Guillain-Barre, Miller-Fisher, and opsoclonus-myoclonus-ataxia syndromes-a case series.
Olbert E, Alhani N, Struhal W
Wien Med Wochenschr. 2023; 174(1-2):30-34.
PMID: 37523107
PMC: 10810910.
DOI: 10.1007/s10354-023-01018-4.
Neuro-ophthalmic Manifestations of Coronavirus Disease 2019 and Its Vaccination: A Narrative Review.
Feizi M, Isen D, Tavakoli M
J Ophthalmic Vis Res. 2023; 18(1):113-122.
PMID: 36937195
PMC: 10020789.
DOI: 10.18502/jovr.v18i1.12731.
Opsoclonus Myoclonus Ataxia Syndrome Due to SARS-CoV-2.
Finsterer J, Scorza F
Neuroophthalmology. 2023; 47(1):1-6.
PMID: 36798867
PMC: 9928447.
DOI: 10.1080/01658107.2022.2128378.
Brain stem encephalitis is a rare complication of COVID-19.
Shamier M, Crijnen Y, Bogers S, IJpelaar J, de Vries J, van der Jagt M
J Neuroimmunol. 2022; 374:578007.
PMID: 36481703
PMC: 9701569.
DOI: 10.1016/j.jneuroim.2022.578007.
Post-COVID-19 Myoclonus-Ataxia Syndrome Responsive to Intravenous Immunoglobulins.
Godani M, Beronio A, Lanza G
Mov Disord Clin Pract. 2022; 9(Suppl 2):S6-S8.
PMID: 36118515
PMC: 9464991.
DOI: 10.1002/mdc3.13534.
Temporal Changes in Brain Perfusion in a Patient with Myoclonus and Ataxia Syndrome Associated with COVID-19.
Osawa K, Sugiyama A, Uzawa A, Hirano S, Yamamoto T, Nezu M
Intern Med. 2022; 61(7):1071-1076.
PMID: 35110499
PMC: 9038453.
DOI: 10.2169/internalmedicine.9171-21.
Neuro-COVID-19.
Shimohata T
Clin Exp Neuroimmunol. 2021; 13(1):17-23.
PMID: 34899999
PMC: 8652810.
DOI: 10.1111/cen3.12676.
Anti-GFAP-antibody positive postinfectious acute cerebellar ataxia and myoclonus after COVID-19: a case report.
Asan L, Klebe S, Kleinschnitz C, Stettner M, Kohrmann M
Ther Adv Neurol Disord. 2021; 14:17562864211062824.
PMID: 34899988
PMC: 8664296.
DOI: 10.1177/17562864211062824.
Movement Disorders Associated with COVID-19.
Salari M, Zaker Harofteh B, Etemadifar M, Sedaghat N, Nouri H
Parkinsons Dis. 2021; 2021:3227753.
PMID: 34790346
PMC: 8592762.
DOI: 10.1155/2021/3227753.
Post-COVID-19 opsoclonus-myoclonus syndrome and encephalopathy associated with leucine-rich glioma-inactivated 1 (LGI-1) antibodies.
Smyth D, Kyaw K, Legister A, MacFarlane G, Sankar U, Patel M
J Neurol Sci. 2021; 430:119982.
PMID: 34543933
PMC: 8440042.
DOI: 10.1016/j.jns.2021.119982.
Anti-GAD associated post-infectious cerebellitis after COVID-19 infection.
Emekli A, Parlak A, Gocen N, Kurtuncu M
Neurol Sci. 2021; 42(10):3995-4002.
PMID: 34328578
PMC: 8322110.
DOI: 10.1007/s10072-021-05506-6.
De Novo Movement Disorders and COVID-19: Exploring the Interface.
Ghosh R, Biswas U, Roy D, Pandit A, Lahiri D, Ray B
Mov Disord Clin Pract. 2021; 8(5):669-680.
PMID: 34230886
PMC: 8250792.
DOI: 10.1002/mdc3.13224.
Post-COVID Opsoclonus Myoclonus Syndrome: A Case Report From Pakistan.
Ishaq H, Durrani T, Umar Z, Khan N, McCombe P, Ul Haq M
Front Neurol. 2021; 12:672524.
PMID: 34163427
PMC: 8215346.
DOI: 10.3389/fneur.2021.672524.
